Corcept Raises Guidance on Korlym Strength; Pipeline Holds Key

What happened

Corcept raised its 2026 revenue guidance after Korlym posted a strong Q1, exceeding expectations. However, the authorized generic launch in June 2024 continues to pressure pricing and volume, a risk highlighted in the DeepValue report. The company's pipeline, particularly relacorilant for Cushing's, is nearing an FDA decision by year-end 2025. While profitability remains solid, the current P/E of ~73x leaves little room for error. The raised guidance provides near-term confidence but does not alter the binary regulatory risk ahead.

Implication

The raised guidance suggests Korlym is holding up better than feared, but generic erosion remains a mid-term concern. The upcoming FDA decision on relacorilant is the key catalyst; approval could justify the premium, while a negative decision would likely lead to a significant sell-off. Management's MOMENTUM initiative and planned ovarian cancer filing add optionality but are not near-term drivers. Given the high P/E, any disappointment in Korlym's trajectory or regulatory setbacks could compress multiples sharply. We maintain a HOLD stance until clearer visibility on the pipeline's regulatory path and commercial potential emerges.

Thesis delta

The strong Q1 Korlym performance and raised guidance provide short-term support but do not materially alter the risk/reward profile. The thesis remains anchored on relacorilant's regulatory outcome and Korlym's erosion pace. Our HOLD stance persists as valuation already reflects optimistic assumptions.